Brainstorm Cell Therapeutics (BCLI) Revenue & Revenue Breakdown
Brainstorm Cell Therapeutics Revenue Highlights
0
Latest Revenue (Q)
$365.00K
Brainstorm Cell Therapeutics Revenue by Period
Brainstorm Cell Therapeutics Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | - | 100.00% |
2022-12-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2020-12-31 | - | 100.00% |
2019-12-31 | - | 100.00% |
2018-12-31 | - | 100.00% |
2017-12-31 | - | 100.00% |
2016-12-31 | - | 100.00% |
2015-12-31 | - | 100.00% |
2014-12-31 | - | 100.00% |
2013-12-31 | - | 100.00% |
2012-12-31 | - | 100.00% |
2011-12-31 | - | 100.00% |
2010-12-31 | - | 100.00% |
2009-12-31 | - | 100.00% |
2008-12-31 | - | 100.00% |
2007-12-31 | - | 100.00% |
2006-12-31 | - | 100.00% |
2005-03-31 | - | 100.00% |
2004-03-31 | - | -100.00% |
2003-03-31 | $82.89K | 261.96% |
2002-03-31 | $22.90K | - |
Brainstorm Cell Therapeutics Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-06-30 | $365.00K | -164.15% |
2024-03-31 | $-569.00K | -265.89% |
2023-12-31 | $343.00K | 100.00% |
2023-09-30 | - | -100.00% |
2023-06-30 | $154.00K | -130.99% |
2023-03-31 | $-497.00K | 100.00% |
2022-12-31 | - | -100.00% |
2022-09-30 | $474.00K | 132.35% |
2022-06-30 | $204.00K | -40.00% |
2022-03-31 | $340.00K | 100.00% |
2021-12-31 | - | 100.00% |
2021-09-30 | - | -100.00% |
2021-06-30 | $87.00K | -82.63% |
2021-03-31 | $501.00K | 100.00% |
2020-12-31 | - | 100.00% |
2020-09-30 | - | -100.00% |
2020-06-30 | $823.00K | 100.00% |
2020-03-31 | - | -100.00% |
2019-12-31 | $-366.00K | -135.33% |
2019-09-30 | $1.04M | 100.00% |
2019-06-30 | - | 100.00% |
2019-03-31 | - | -100.00% |
2018-12-31 | $170.00K | -116.65% |
2018-09-30 | $-1.02M | -1891.23% |
2018-06-30 | $57.00K | 100.00% |
2018-03-31 | - | -100.00% |
2017-12-31 | $975.00K | 644.27% |
2017-09-30 | $131.00K | 100.00% |
2017-06-30 | - | 100.00% |
2017-03-31 | - | -100.00% |
2016-12-31 | $212.00K | 100.00% |
2016-09-30 | - | 100.00% |
2016-06-30 | - | 100.00% |
2016-03-31 | - | 100.00% |
2015-12-31 | - | 100.00% |
2015-09-30 | - | 100.00% |
2015-06-30 | - | 100.00% |
2015-03-31 | - | 100.00% |
2014-12-31 | - | 100.00% |
2014-09-30 | - | 100.00% |
2014-06-30 | - | 100.00% |
2014-03-31 | - | 100.00% |
2013-12-31 | - | 100.00% |
2013-09-30 | - | 100.00% |
2013-06-30 | - | 100.00% |
2013-03-31 | - | 100.00% |
2012-12-31 | - | 100.00% |
2012-09-30 | - | 100.00% |
2012-06-30 | - | 100.00% |
2012-03-31 | - | 100.00% |
2011-12-31 | - | 100.00% |
2011-09-30 | - | 100.00% |
2011-06-30 | - | 100.00% |
2011-03-31 | - | 100.00% |
2010-12-31 | - | 100.00% |
2010-09-30 | - | 100.00% |
2010-06-30 | - | 100.00% |
2010-03-31 | - | 100.00% |
2009-12-31 | - | 100.00% |
2009-09-30 | - | 100.00% |
2009-06-30 | - | 100.00% |
2009-03-31 | - | 100.00% |
2008-12-31 | - | 100.00% |
2008-09-30 | - | 100.00% |
2008-06-30 | - | 100.00% |
2008-03-31 | - | 100.00% |
2007-12-31 | - | - |
Brainstorm Cell Therapeutics Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
HOWL | Werewolf Therapeutics | $19.94M | $1.14M |
MREO | Mereo BioPharma Group | $10.00M | - |
GBIO | Generation Bio | $5.90M | $4.09M |
CUE | Cue Biopharma | $5.49M | $3.34M |
HCWB | HCW Biologics | $2.84M | $426.42K |
GMDA | Gamida Cell | $1.78M | $890.00K |
LIFE | aTyr Pharma | $353.00K | $235.00K |
CKPT | Checkpoint Therapeutics | $103.00K | - |
CRVS | Corvus Pharmaceuticals | - | - |
GRI | GRI Bio | - | - |
CCCC | C4 Therapeutics | - | - |
XFOR | X4 Pharmaceuticals | - | $560.00K |
ALDX | Aldeyra Therapeutics | - | - |
ANTX | AN2 Therapeutics | - | - |
BCAB | BioAtla | - | $11.00M |
DAWN | Day One Biopharmaceuticals | - | $20.07M |
CNTB | Connect Biopharma | - | - |
BCLI | Brainstorm Cell Therapeutics | - | $365.00K |
INZY | Inozyme Pharma | - | - |
DBTX | Decibel Therapeutics | - | - |
PASG | Passage Bio | - | - |
TRVI | Trevi Therapeutics | - | - |
TERN | Terns Pharmaceuticals | - | - |
CELC | Celcuity | - | - |
EWTX | Edgewise Therapeutics | - | - |